Phase 2 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who are receiving their very first kidney transplant, whether the kidney comes from a living or deceased donor
- People who agree to use contraception during the study and for at least 90 days after the last dose of the study drug
Who may not be able to join:
- People whose transplant plan includes immune-suppressing induction therapy other than the specific drug (rATG) assigned by this study
- People currently taking immune-suppressing medications or biological therapies, except for a low daily dose of prednisone (5 mg or equivalent)
- People who have previously been treated with AT 1501 or any other therapy targeting a protein called CD40LG
- People who have previously received a bone marrow transplant or any other organ transplant (including a prior kidney), or who will be receiving more than one organ at the same time
- People who will receive a kidney that has been stored outside the body for more than 30 hours before transplant
- People who will receive a kidney from certain higher-risk donors, including donors whose heart stopped before organ retrieval (donation after cardiac death), donors whose blood type does not match the recipient, donors aged 60 or over, or donors aged 50–59 who also had at least two of the following: a stroke as the cause of death, a history of high blood pressure, or elevated kidney function markers at the time of death (confirm with trial site for exact donor criteria)
- People whose donor kidney is a perfect genetic match across all relevant markers (zero HLA mismatch)
- People with a medical condition that requires them to take steroid medication at a dose higher than 5 mg prednisone (or equivalent) per day on an ongoing basis
- People with a history of blood clotting events, a known condition that increases clotting risk, or a condition requiring long-term use of blood-thinning medication
- People whose pre-transplant blood test results show a positive crossmatch caused by HLA antibodies, or the presence of donor-specific antibodies
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 949-238-8090
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety Incidences; Pharmacokinetic- PK profile; Pharmacokinetic- Area under the plasma concentration; Pharmacokinetic- Cmax; Pharmacokinetic- Tmax; Pharmacokinetic- Ke; Pharmacokinetic- (t1/2); Pharmacokinetic- CL; Pharmacokinetic- (Vdss)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.